CHARLES RIVER LABORATORIES (CRL) Forecast, Price Target & Analyst Ratings
NYSE:CRL • US1598641074
152.66 USD
-16.25 (-9.62%)
At close: Mar 12, 2026
152.66 USD
0 (0%)
After Hours: 3/12/2026, 8:04:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHARLES RIVER LABORATORIES (CRL).
Forecast Snapshot
Consensus Price Target
$206.27
+ 35.12% Upside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$1.95
Revenue Estimate990.05M
ChartMill Buy Consensus
78.26%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$206.27
Upside
+ 35.12%
From current price of $152.66 to mean target of $206.27, Based on 23 analyst forecasts
Low
$158.01
Median
$204.00
High
$278.25
Price Target Revisions
1 Month
-6.85%
3 Months
6.76%
Price Target Summary
23 Wall Street analysts provided a forecast for the next 12 months for CRL. The average price target is 206.28 USD. This implies a price increase of 35.12% is expected in the next year compared to the current price of 152.66.
The average price target has been revised upward by 6.76% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
78.26%
CRL was analyzed by 23 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about CRL.
In the previous month the buy percentage consensus was at a similar level.
CRL was analyzed by 23 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | UBS | Maintains | Neutral -> Neutral |
| 2026-02-20 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-20 | Mizuho | Maintains | Neutral -> Neutral |
| 2026-02-19 | Barclays | Maintains | Overweight -> Overweight |
| 2026-02-19 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-01-16 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-18 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-12-15 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-15 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-10 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-06 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-06 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-06 | Baird | Upgrade | Neutral -> Outperform |
| 2025-10-17 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-10-06 | William Blair | Upgrade | Market Perform -> Outperform |
| 2025-10-03 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-02 | Barclays | Upgrade | Equal-Weight -> Overweight |
| 2025-09-09 | Jefferies | Upgrade | Hold -> Buy |
| 2025-08-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-07 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-07-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-07-09 | Citigroup | Upgrade | Neutral -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$1.95
Revenue Estimate990.05M
Revenue Q2Q0.60%
EPS Q2Q-16.57%
Number of Analysts15
Next Earnings Revisions
Revenue (1 Month)
-1.59%
Revenue (3 Months)
-1.68%
EPS (1 Month)
-24.41%
EPS (3 Months)
-24.74%
Next Earnings Summary
CRL is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is 1.95 USD and the consensus revenue estimate is 990.05M USD.
The next earnings revenue estimate has been revised downward by 1.68% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.129B 3.86% | 4.05B -1.92% | 4.015B -0.85% | 4.1B 2.11% | 4.221B 2.95% | 4.406B 4.38% | 4.624B 4.95% | 4.816B 4.15% | 5.249B 8.99% | 5.587B 6.44% | 5.958B 6.64% | |
| EBITDA YoY % growth | 973.446M 1.02% | 912.573M -6.25% | 905.462M -0.78% | 988.62M 9.18% | 1.056B 6.82% | 1.086B 2.84% | 1.186B 9.21% | 1.265B 6.66% | 1.353B 6.96% | 1.472B 8.80% | 1.616B 9.78% | |
| EBIT YoY % growth | 659.322M -0.06% | 550.832M -16.45% | 502.15M -8.84% | 795.94M 58.51% | 873.12M 9.70% | 906.14M 3.78% | 1.002B 10.58% | 1.084B 8.18% | N/A | N/A | N/A | |
| Operating Margin | 15.97% | 13.60% | 12.51% | 19.41% | 20.69% | 20.57% | 21.67% | 22.51% | N/A | N/A | N/A | |
| EPS YoY % growth | 10.65 -4.31% | 10.32 -3.10% | 10.28 -0.39% | 11.15 8.47% | 12.16 9.01% | 13.27 9.19% | 14.42 8.66% | 16.05 11.25% | 18.56 15.69% | 20.62 11.10% | 22.50 9.11% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.95 -16.57% | 2.93 -6.12% | 2.77 13.94% | 2.74 14.67% | 2.84 45.36% | 2.94 0.37% | 3.00 8.23% | 3.00 9.44% |
| Revenue Q2Q % growth | 990.05M 0.60% | 1.034B 0.18% | 1.035B 3.00% | 1.029B 3.50% | 1.06B 7.07% | 1.082B 4.64% | 1.092B 5.51% | 1.094B 6.32% |
| EBITDA Q2Q % growth | 199.16M -9.01% | 263.2M -29.29% | 255.8M -46.27% | 250.33M -52.18% | 261.22M 31.16% | 267.83M 1.76% | 275.61M 7.74% | 274.35M 9.60% |
| EBIT Q2Q % growth | 152.32M 54.62% | 218.76M 65.31% | 211.26M 39.83% | 200.64M 66.89% | 209.92M 37.82% | 217.2M -0.71% | 216.34M 2.40% | 208.12M 3.73% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
8.89%
EPS Next 5 Year
9.31%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
2.87%
Revenue Next 5 Year
3.54%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
11.29%
EBIT Next 5 Year
9.93%
CHARLES RIVER LABORATORIES / CRL Forecast FAQ
What is the price target for CRL stock?
23 analysts have analysed CRL and the average price target is 206.28 USD. This implies a price increase of 35.12% is expected in the next year compared to the current price of 152.66.
When does CHARLES RIVER LABORATORIES (CRL) report earnings?
CHARLES RIVER LABORATORIES (CRL) will report earnings on 2026-05-05, before the market open.
What are the consensus estimates for CHARLES RIVER LABORATORIES (CRL) next earnings?
The consensus EPS estimate for the next earnings of CHARLES RIVER LABORATORIES (CRL) is 1.95 USD and the consensus revenue estimate is 990.05M USD.
Can you provide the expected long term growth rate for CHARLES RIVER LABORATORIES stock?
The expected long term growth rate for CHARLES RIVER LABORATORIES (CRL) is 2.87%.